International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: http://www.sciepub.com/journal/ijcd Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
Go
International Journal of Celiac Disease. 2020, 8(2), 58-59
DOI: 10.12691/ijcd-8-2-5
Open AccessArticle

The Utility of CCP Antibodies in Autoimmune Diseases

Lucia Maria Sur1, 2, Remus Gaga1, 2, , Genel Sur1, 2 and Emanuela Floca1, 2

1University of Medicine and Pharmacy “Iuliu Hațieganu”, Department of Pediatrics ,Cluj-Napoca, Romania

2Emergency Clinical Hospital for Children, Cluj-Napoca

Pub. Date: June 25, 2020

Cite this paper:
Lucia Maria Sur, Remus Gaga, Genel Sur and Emanuela Floca. The Utility of CCP Antibodies in Autoimmune Diseases. International Journal of Celiac Disease. 2020; 8(2):58-59. doi: 10.12691/ijcd-8-2-5

Abstract

Autoimmune diseases have a constellation of immunological changes that make possible the appearance of clinical manifestations. There are often similarities of clinical manifestations in these autoimmune diseases as possible associations of them during evolution.

Keywords:
autoimmune diseases clinical manifestations associations child

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Lerner A, Jeremias P, Torsten M. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease 2015; 3: 151-155.
 
[2]  Sur L, Floca E, Sur G, Rednic S. Serological and Genetic Evidence of Celiac Disease in Juvenile Arthritis and Rheumatoid Arthritis. International Journal of Celiac Disease 2016; 4: 82-83.
 
[3]  Sur L, Floca E, Sur G. Transfer of Patients with Autoimmune Diseases from the Pediatrician to Adult Health Care Service. International Journal of Celiac Disease 2017; 5: 33-34.
 
[4]  Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J. 2017; 34: 90-101.
 
[5]  Wang Y, Pei F, Wang X, Sun Z, Hu C, Dou H. Meta-Analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody for Juvenile Idiopathic Arthritis. J Immunol Res. 2015; 2015: 1-12.
 
[6]  Hamooda M, Fouad H, Galal N, Sewelam N, Megahed D. Anti-cyclic citrullinated peptide antibodies in children with Juvenile Idiopathic Arthritis. Electron physician. 2016; 8: 2897-2903.
 
[7]  van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum. 2004; 50: 709-715.
 
[8]  Gupta R, Thabah MM, Vaidya B, Gupta S, Lodha R, Kabra SK. Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Indian J Pediatr. 2010; 77: 41-44.
 
[9]  Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL. Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2011; 9: 8.
 
[10]  Ozawa R, Inaba Y, Mori M, Hara R, Kikuchi M, Higuchi R, Miyamae T, Imagawa T, Fujiwara T, Saito T, Yokota S. Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis. Mod Rheumatol. 2012; 22: 558-64.
 
[11]  Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, McNally B, Hill HR, Bohnsack J, Prahalad S. Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2012; 10: 29.
 
[12]  Gilliam BE, Chauhan AK, Moore TL. Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2013; 11: 31.
 
[13]  Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi MO, Meroni PL. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2002; 61: 608-611.
 
[14]  van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, Dijkmans B, van Venrooij WJ. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol. 2003; 30: 825-828.
 
[15]  Yasui K, Sakata S, Ochi H, Itamura S, Hirai K, Takenaka M, Mitani O, Ogawa K, Iyoda K. Onset of polyarticular juvenile idiopathic arthritis with both anti-cyclic citrullinated peptide antibodies and rheumatoid factor in a 3-year-old girl. Pediatr Rheumatol. 2012; 10: 41.
 
[16]  Yasumura J, Yashiro M, Okamoto N, Shabana K, Umebayashi H, Iwata N, Okura Y, Kubota T, Shimizu M, Tomiita M, Nakagishi Y, Nishimura K, Hara R, Mizuta M, Yasumi T, Yamaide F, Wakiguchi H, Kobayashi M, Mori M. Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ). Pediatr Rheumatol Online J. 2019; 17: 15.
 
[17]  Hisa K, Yanagimachi MD, Naruto T, Miyamae T, Kikuchi M, Hara R, Imagawa T, Yokota S, Mori M. PADI4 and the HLA-DRB1 shared epitope in juvenile idiopathic arthritis. PLoS One. 2017; 12: e0171961.